Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need. Source
No articles found.
Halozyme is a clinical-stage biotechnology company focused on developing and comme...
Halozyme is a clinical-stage biotechnology comp...
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committ...
Verastem Oncology (Nasdaq: VSTM) is a commercia...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Join the National Investor Network and get the latest information with your interests in mind.